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Rupture of unstable plaques may lead to myocardial infarction or stroke and is the leading cause of morbidity and mortality in western
countries. Thus, there is a clear need for identifying these vulnerable plaques before the rupture occurs. Atherosclerotic plaques are a chal-
lenging imaging target as they are small and move rapidly, especially in the coronary tree. Many of the currently available imaging tools for
clinical use still provide minimal information about the biological characteristics of plaques, because they are limited with respect to spatial
and temporal resolution. Moreover, many of these imaging tools are invasive. The new generation of imaging modalities such as magnetic
resonance imaging, nuclear imaging such as positron emission tomography and single photon emission computed tomography, computed
tomography, fluorescence imaging, intravascular ultrasound, and optical coherence tomography offer opportunities to overcome some of
these limitations. This review discusses the potential of these techniques for imaging the unstable plaque.
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Need for high resolution imaging
of plaque biology
Acute coronary syndromes (ACS) are the most frequent cause of
hospitalization in western countries and may be complicated by
acute heart failure or sudden cardiac death. The underlying mech-
anism of ACS is plaque rupture, endothelial erosion, and/or intra-
plaque haemorrhage with partial or complete occlusion of an
epicardial coronary artery.
Mortality of the sequelae of ACS remains high. Instead of prevent-
ing ACS, we are frequently limited to diagnose evolving ACS by
relying on electrocardiogram changes, chest pain, and markers of
cardiomyocyte necrosis. In order to limit the damage, this leaves
us with ‘late’ measures such as percutaneous interventions. Never-
theless, in the best case scenario, we fix the problem (thrombotic
coronary artery occlusion) after the event (plaque rupture or
erosion) occurred. Instead, prevention of this event with the identi-
fication of patients at risk for plaque rupture would be desirable.
Vulnerable plaques are characterized by increased inflammatory
infiltrates (i.e. mainly monocytes/macrophages, some T-cells, and
neutrophils). Upon ingestion of modified LDL, macrophages
become foam cells and release inflammatory cytokines and pro-
teases that induce fibrous cap thinning.1,2 Lipid-loaded foam cells
eventually die, thereby leading to growth of the necrotic core.
Relying on inflammation as a central pathogenic aspect of plaque
vulnerability, circulating inflammatory biomarkers of vulnerable
plaques have been identified. They provide valuable diagnostic
and prognostic information.3 However, they do not provide
insight in the anatomic localization of vulnerable plaques. Thus,
timely and anatomically precise imaging of vulnerable plaques is a
medical need, since angiographic and pathological studies demon-
strate that coronaries frequently occlude acutely without flow-
limiting stenoses.4,5 These findings suggest that the biological
characteristics of plaques rather than the degree of luminal nar-
rowing determine the risk for coronary occlusion. X-ray coronary
angiography only visualizes the coronary lumen and provides
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minimal structural or biological information about the vessel wall.
Thus, high resolution imaging of plaques reporting on critical
lesion biology may identify patients at risk for ACS. Although a
number of recent reviews have summarized novel imaging
approaches aimed at achieving these goals,6 –8 we here focus on
novel imaging techniques that come close to fulfilling this
promise in the near future (Table 1).
Targeted fluorescence imaging
Fluorescence imaging has revolutionized preclinical research
because it is sensitive, cost-effective and can be used over a
wide range from microscopic to macroscopic and ex vivo to
in vivo applications. Currently, the main impact of optical imaging
of inflamed atherosclerotic plaques is preclinical. Intravital
microscopy9 and whole mouse tomographic imaging10 have tar-
geted the key aspects of lesion biology. In addition, preclinical
tools such as ex vivo immunofluorescence microscopy and flow
cytometry are frequently used to validate novel imaging agents in
rodent models. In particular, fluorescence molecular tomography
holds promise for non-invasive imaging of murine models of ather-
osclerosis, because it allows quantification of tracer fluorochrome
concentrations.11 Comparable to positron emission tomography
(PET)–computed tomography (CT), recent addition of hybrid ana-
tomical imaging, for instance fluorescence-mediated tomography–
CT, allows to exactly identify the anatomic source of molecular
signals (Figure 1A).
Clinical translation of optical imaging has been hampered by
physical hurdles, as light does not penetrate more than 8 cm of
tissue. Although the use of fluorochromes in the near-infrared
spectrum optimizes tissue penetrance and minimizes autofluores-
cence,12 the coronary artery tree is out of reach for non-invasive
fluorescent sensing. However, carotid arteries should be accessible
for non-invasive fluorescent imaging as they are closer to the body
surface.
Recent advances in catheter-based technology allow to probe
fluorescence in the vascular wall from inside the vessel
(Figure 1B–E).13 For situations in which invasive angiography is
needed, fluorescent sampling of the vascular wall may develop
into a valuable add-on as fluorescent probes can identify several
hallmarks of lesion inflammation. Among these, activatable pro-
tease reporters are particularly promising.14 These probes are
injected in a quenched, inactive state. Fluorochromes are attached
to a polypeptide backbone, which is targeted by the protease of
interest. Upon cleavage of the backbone by the enzyme, fluoro-
chromes are liberated and gain a higher distance to each other,
which renders them excitable with a laser in the appropriate wave-
length.11 After excitation, they emit light at a higher wavelength,
detectable with appropriate charge-coupled device cameras or
catheter sensors. In a hypothetical clinical scenario, pull-back
scans of the coronary tree after systemic injection of an activatable
fluorescent protease sensor may locate inflamed, vulnerable
lesions in proximal coronary segments that have a high probability
of causing ischaemic complications and therefore may warrant
therapeutic intervention.
Nuclear imaging
The foremost advantage of nuclear imaging is its excellent sensi-
tivity, which translates into the detection of sparse targets in the
nanomolar range with low tracer doses. Until recently, single
photon emission computed tomography (SPECT) and PET
imaging of vascular biology were hampered by the low spatial res-
olution (4–10 mm) and limited ability to visualize anatomical detail.
However, hybrid imaging of CT and magnetic resonance imaging
(MRI) in dual modality systems exactly attribute the molecular
signal to the anatomic source (Figure 2A–C ). This progress has
led to increased interest in the development of nuclear tracers
for vascular applications.
18FDG (fluorodeoxyglucose) is a glucose analogon that enriches
in metabolically active cells. It is clinically approved for cancer
imaging and has been explored for imaging inflamed plaques with
enhanced metabolism. Experimental and clinical studies suggest
that 18FDG enriches in plaque macrophages and correlates with
neovessel content.15– 17 A limitation of 18FDG relates to its mod-
erate specificity18 and the high background uptake in the myocar-
dium, although some dietary measures may reduce cardiomyocyte
uptake (Figure 2A and B).19 18FDG is currently the only readily
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Table 1 Tools for imaging the unstable plaque
Technique Specificity Sensitivity Spatial Res Temperature Res Penetration Clinical use Specific features
Fluorescence I þþþþ þþþ þþ þ þ (þ) Experimental
Nuclear I þþþþ þþþþ þ þ þþþþ þþþ Radiation
MRI þþ þþ þþþ þþþ þþþþ þþ No radiation
CT þ þ þþþ þþþ þþþþ þþþ Radiation
VH-IVUS þþ þþ þþ þþþ þþ þþþ Invasive
OCT þþ þþþ þþþþ þþ þ þþ Invasive, flushing
OFDI þþ þþþ þþþþ þþþþ þ þ Invasive, no flushing
Angioscopy þ þ þ þþþ (þ) (þ) Invasive
Thermography þ þ þ þ þþ (þ) Invasive
MRI, magnetic resonance imaging; CT, computed tomography; VH-IVUS virtual histology-intravascular ultrasound; OCT, optical coherence tomography; OFDI, optical frequency
domain imaging; temp, temporal; res, resolution.
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available PET tracer for atherosclerotic studies and provides the
possibility to explore PET–CT imaging for vascular targets in
patients. Therefore, the number of clinical studies using 18FDG is
on the rise.20,21
Several tracers that target specific aspects of lesion biology are
currently tested. Vascular cell adhesion molecule-1 (VCAM-1) is
expressed early in the course of atherosclerotic disease, is
favourably positioned on endothelial cells lining the inflamed
plaque and therefore provides unhindered access for probes
from the blood. Most importantly, VCAM-1 is central to both
development and complications of atherosclerotic plaques.
Monocytes/macrophages that are recruited into the subendothe-
lial layer of the arterial wall bind to VCAM-1 via the integrin
VLA-4, a decisive step for cell extravasation. Vascular cell
adhesion molecule-1 had been targeted with a variety of
probes with magnetic, optical, and ultrasound reporters.22– 24
More recently, a PET tracer has been developed25, termed
18F-4V. Its good affinity, favourable pharmacokinetics and the
choice of target make 18F-4V a promising candidate for trans-
lation (Figure 2D–G).
The trimodal nanoparticulate PET/MRI/optical agent 64Cu-TNP
was used to image a target downstream of VCAM-1, the presence
of lesional macrophages.26 The fluorescent properties of
64Cu-TNP have been exploited to quantify the target cells by
flow cytometric profiling of digested aortic plaques. Interestingly,
this tracer is primarily taken up into macrophages. In a direct
Figure 2 Nuclear imaging of plaque biology. (A–C) Clinical 18FDG PET–CT imaging in a patient with coronary artery disease shows uptake of
the tracer in a stenotic segment (confirmed by angiography).19 (D–G) In vivo PET–CT imaging with the VCAM-1 targeted tracer 18F-4V in ather-
osclerotic mice with and without statin treatment. (D, F) Short-axis view of aortic root, (E and G) long-axis view. Statin therapy reduced
VCAM-1 expression and consecutively PET signal. (H ) SPECT imaging of apoptosis in the carotid artery of a TIA patient.27 (I) In vivo
MMP-targeted microSPECT-CT 3 weeks following carotid injury in the apoE2/2 mouse. Arrows point to the injured left (L) and non-injured
right (R) carotid arteries.28
Figure 1 Fluorescence imaging of protease activity. (A) In vivo fluorescence molecular tomography (FMT) of an atherosclerotic mouse after
injection of a cathepsin-targeted protease reporter. Hybrid FMT–CT imaging shows activation of the sensor in the aortic root, a site of strong
inflammatory atherosclerosis in this model.76 (B–E) Catheter-based sensing of fluorescence protease reporters in a rabbit model of arterial
injury. The balloon injury was applied in the iliac artery (B). During pull back of a fluorescence sensing catheter, high signal was observed
(C), corroborated by ex vivo fluorescence reflectance imaging (D, E).13
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comparison with high-field T2*-weighted MRI, the detection
threshold was 50 times lower for PET detection.26
Plaque foam cells eventually undergo apoptosis and form a
necrotic core. Probes have been explored that target apoptosis
using annexin-V as affinity ligand. Annexin-V binds to phosphatidyl-
serine that is normally hidden on the inside of the cell membrane.
In one small clinical study, increased uptake of 99mTc-labelled
annexin-V in the carotid artery correlated with histological signs
of apoptosis after endarterectomy.27
Much of the mayhem caused by macrophages inside lesions is
inflicted through protease activity. Released by monocytes/macro-
phages, these enzymes digest extracellular matrix and weaken the
fibrous cap that protects the plaque against rupture. Several groups
have developed small molecule inhibitors of matrix metalloprotei-
nases and labelled these with radiotracers for SPECT imaging.28– 30
Other matrix proteins such as the extradomain B of fibronectin31
and the C domain of tenascin-C32 are also increased in advanced
plaques. Because these agents can visualize inflamed atherosclero-
tic plaques in mice, they may provide attractive opportunities for
imaging advanced plaques in patients.
Macrophages deliver high payloads of vascular endothelial growth
factor and may therefore stimulate growth of blood vessels. The
leaky character of plaque neovessels has been inferred to promote
intraplaque haemorrhage, further exacerbating inflammation.33
Upon formation of these new microvessels, involved endothelial
cells express a variety of integrins on their surface, which have
been targeted using nuclear probes.34 Frequently, affinity ligands
binding to integrins incorporate the amino acid sequence
Arg-Gly-Asp (RGD), which binds to alphavbeta3.
35 This integrin is
also expressed by leucocytes, smooth muscle cells, and platelets.
Some of these tracers have already been used in clinical studies.36
Taken together, nuclear imaging techniques hold great promise
for non-invasive detection of inflamed, rupture-prone athero-
sclerotic lesions. Their limited ability to provide anatomical detail
has been overcome by hybrid CT or MRI. Although we are
seeing the first PET images of coronary arteries in patients, the
rapid motion and small size of these vascular territories still pose
greater challenges than imaging of the carotid arteries.
Magnetic resonance imaging
Magnetic resonance imaging is a safe and non-invasive technique
that operates without X-rays. Using MRI, contrast between differ-
ent tissues can easily be obtained and amplified using contrast
agents. These characteristics render MRI well positioned for moni-
toring atherosclerotic disease progression or to guide therapy.
Since MRI is a relatively signal-insensitive technique when com-
pared with CT or PET, long scanning times are required for
improving spatial resolution.
The current gold standard for the identification of coronary artery
stenoses is X-ray coronary angiography. However, it is invasive and
associated with significant costs and radiation exposure. Magnetic
resonance imaging has the potential to overcome some of these
limitations. However, the technical challenges related to spatial res-
olution, contrast generation, and motion artefact suppression are
significant. To date, results from the only multicenter trial37
suggest that MRI can reliably identify significant proximal luminal
disease and rule out patients without significant proximal or three-
vessel disease. However, the specificity of MRI is still relatively low.
More advanced and promising approaches include whole heart cor-
onary MR angiography38 (Figure 3A–C ), as well as the use of both
high magnetic field strength39 and molecular imaging agents.40
On conventional coronary MRI, there is little contrast between
the luminal blood and the coronary vessel wall. Using sophisti-
cated magnetization preparation schemes,41 a high ‘dark-blood’
contrast between the coronary blood pool and the coronary
vessel wall can be obtained.42 Building on this technique, positive
coronary arterial remodelling was successfully quantified in
patients with mild coronary artery disease.43 Furthermore, this
technique visualized differences in coronary vessel wall remodel-
ling in high-risk diabetic patients with and without nephropathy
(Figure 3D and E).44
Magnetic resonance imaging was further refined for resolving
plaque structure: multisequence MRI was able to detect unstable
fibrous caps in advanced human carotid plaques.45 In addition,
after selecting patients with carotid artery stenosis via ultrasound,
bilateral carotid MRI scans at 1.5 T identified complex lesions in a
substantial number of arteries in the absence of high-grade narrow-
ing.46 Moreover, tools have been developed for MRI of coronary
plaque components. Gadolinium (Gd) clearance is delayed in
regions of carotid atherosclerotic plaques with thin fibrous caps
(,60 mm)47 which was attributed to both inflammation and endo-
thelial dysfunction. Later on, delayed signal enhancement in the
coronary vessel wall after Gd identified patients with established
coronary artery disease (Figure 3F).48,49 Similarly, enhanced con-
trast uptake was found in the coronary vessel wall of patients 6
days after AMI50 and decreased 3 months later parallel to the
declines in C-reactive protein. Thus, delayed Gd enhancement of
the coronary vessel wall may be useful for visualization of inflam-
matory activity in patients with ACS. The question remains
whether delayed Gd enhancement identifies plaques at risk for
rupture. Of note, for some of these applications, the association
between Gd exposure during MRI and the rare development of
nephrogenic systemic fibrosis has to be considered when using
Gd for plaque characterization.51,52
A number of MRI-based strategies have been proposed for
detecting inflammation in atherosclerotic plaques using targeted
gadolinium agents53 and superparamagnetic nanoparticles which
are taken up by macrophages.54 This notion was extended recently
using a positive contrast off-resonance imaging sequence (inversion
recovery with ON-resonant water suppression-MRI).55 In combi-
nation with intravenously injected superparamagnetic nanoparti-
cles (monocrystalline iron-oxide nanoparticles—MION-47), this
technique generated positive contrast in areas of plaque macro-
phages56 in an animal model. Currently, the development of con-
trast agents that ‘highlight’ specific plaque components for MRI
seems promising. So far, molecular agents targeted to adhesion
molecules,23 or high-density lipoprotein,57 matrix metalloprotei-
nases,58 and macrophage scavenger receptors59 have been tested
at the preclinical level, and agents targeted to fibrin60 and macro-
phages61 have already been used in patients.
In summary, translation of molecular MRI to clinical applications
appears particularly promising in combination with above-
mentioned MRI techniques for coronary vessel wall imaging.
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Computed tomography
Recent technological advances including multi-detector CT, dual-
source CT, and ECG-gated CT led to a growing interest in CT
as a tool for non-invasive characterization of coronary artery
disease. When compared with MRI, CT is more signal-efficient
and high-spatial resolution images of the entire coronary arterial
tree can be obtained in a short period of sustained respiration,
thereby markedly reducing scanning time. However, exposure to
X-ray remains a concern and iodinated contrast agents are
needed. Thus, imaging of low-risk subjects and repeated
studies should not be performed.62 There has been a large
number of recent single centre trials that examined the sensi-
tivity and specificity of coronary CT angiography (CTA) in com-
parison to X-ray angiography. Consistent with the results from
these studies, findings from a recent international multicenter
trial63 suggest that coronary 64-row multi-detector CTA is accu-
rate in identifying coronary stenoses and characterizing disease
severity in symptomatic patients who have coronary calcium
scores of 600 or less. However, multi-detector CTA cannot cur-
rently be used as a substitute of conventional coronary angiogra-
phy given its negative predictive value of 83% and positive
predictive value of 91%.
With iodinated contrast agents, Hounsfield units can be
measured directly and the expectation was that plaques or their
components can be characterized based on X-ray attenuation.
Due to considerable overlap in the attenuation spectrum of lipid
and fibrous tissue,64 most of the contemporary CT methods unfor-
tunately cannot identify unstable plaques. However, an iodinated
contrast agent with specificity for plaque macrophages recently
improved visualization of plaque macrophages in an atherosclerotic
rabbit model.65
Intravascular ultrasound
Intravascular ultrasound (IVUS) is an invasive, catheter-based
imaging technique that provides two-dimensional cross-sectional
images of the whole arterial wall. The high accuracy of IVUS to
measure lumen, plaque, and vessel area as well as morphological
features is established. Given its axial resolution 100 mm using
40 MHz detectors, IVUS has the ability to localize plaques and
quantify plaque burden. Moreover, IVUS is able to identify echolu-
cent areas that represent lipid-rich plaques and may thus have the
potential to identify unstable plaques by quantifying necrotic cores
in coronary arteries.66 However, given the limited specificity of
Figure 3 Visualization of a coronary atherosclerosis by MRI. (A) Curved multiplanar reconstruction of a whole-heart coronary MRA data
acquisition shows a stenosis in the left anterior descending (LAD) artery (arrow). (B) Volume-rendering method in the same patient demon-
strates three-dimensional view of the LAD with stenosis (white arrows). (C ) X-ray coronary angiography confirms the stenosis of the proximal
LAD (arrowhead),38 reprinted with permission from Elsevier. (D and E) Coronary vessel wall images of the proximal RCA in two other subjects
without coronary luminal stenoses; (D) a 58-year-old man with long-standing type 1 diabetes and normoalbuminuria and (E) a 44-year-old man
with long-standing type 1 diabetes and diabetic nephropathy. In (D), there is no evidence of atherosclerotic plaque. However, an increased
atherosclerotic plaque burden is seen in (E). The anterior and posterior RCA walls are indicated by arrows44 reprinted with permission
from Wolters Kluwer Health. (F ) Delayed focal gadolinium late enhancement of the proximal RCA (arrow) is shown in another patient
with X-ray defined coronary artery disease in the same location,48 reprinted by permission of the European Society of Cardiology.
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echolucency, the restricted access to proximal coronary segments,
its moderate sensitivity to detect lipid-rich lesions and fibrous cap
thickness, this technique has not yet reached clinical routine.
Advances in IVUS technology, i.e. spectral analysis of the IVUS
backscatter radiofrequency signal have further improved the
tissue characterization of plaques to a degree that it is referred
to as virtual histology (VH-IVUS); the raw signals from reflection
of ultrasound waves are transduced into a colour-coded represen-
tation of plaque characteristics.67 During recent years, VH-IVUS
has been extensively validated. Ex vivo analyses of human plaque
specimens showed that VH-IVUS could identify plaque com-
ponents such as lipids, fibrous tissue, calcifications, and the necro-
tic core.68 Some limitations were reported in a porcine model of
complex coronary lesions in which VH-IVUS was not accurate in
detecting the relative amount of specific plaque components
within each corresponding histological specimen.69 In patients
with ACS or stable coronary artery disease, VH-IVUS detected
thin-cap fibroatheroma as a morphological plaque feature associ-
ated with high-risk ACS presentation.70 On the basis of these find-
ings, VH-IVUS emerges as a promising tool for further
characterization of vulnerable plaques.
Optical coherence tomography
Optical coherence tomography (OCT) represents a new optical
analogue of ultrasound imaging and has been introduced as an
intravascular imaging modality with excellent spatial resolution
(10–15 mm) that provides cross-sectional images of the coronary
arteries. When compared with IVUS, OCT facilitates the identifi-
cation of intimal hyperplasia, the internal and external elastic
laminae as well as echolucent regions. Optical coherence tomogra-
phy can also detect and quantify the key pathological features of
vulnerable plaques such as a thin fibrous cap (,65 mm) and a
large lipid pool.71 The safety and feasibility of using an intravascular
OCT image wire system has been demonstrated in ACS patients as
well as in patients with acute myocardial infarction.72 Furthermore,
OCT has been used successfully to assess culprit lesion mor-
phology in vivo73 and restenosis after stenting.74
A very attractive upgrade of OCT has recently been introduced:
Fourier-domain-OCT, also called optical frequency domain imaging
(OFDI) works at much higher frame rates (.100 frames/s). This
technique enables rapid, three-dimensional imaging of long coron-
ary segments from 3 to 7 cm at pullback rates .20 mm/s after a
brief, non-occlusive saline purge,75 therefore eliminating the neces-
sity to use a closure balloon.
Imaging the unstable plaque—
present and future
How can aforementioned imaging modalities be used for imaging
the unstable plaque?
Among the anatomical imaging tools (Figure 4, right), CT and MRI
hold promise given their non-invasive character. Whereas MRI
provides excellent soft tissue contrast and a better contrast resol-
ution, CT allows much shorter scanning times. However, the
hazard of exposing patients to radiation is a concern. The invasive
approaches IVUS-VH and OCT/OFDI offer high-excellent spatial
resolution. The combination of anatomical with biological imaging
using hybrid techniques, i.e. PET–CT or PET–MRI, appears to
be particularly attractive. Among those, targeted imaging that
measures inflammation holds the greatest promise to identify
unstable plaques by reporting on macrophages and other mechan-
isms involved in plaque vulnerability (Figure 4, left) such as adhesion
molecules, proteases, and matrix components.
How should the patients be selected for plaque imaging and
how should we manage these unstable plaques?
Optimal patient selection may be reached by integrating individ-
ual risk factors, clinical data, and key plasma biomarkers. Once
Figure 4 Techniques for imaging the unstable plaque. This scheme illustrates morphological and biological tools for visualizing vulnerable
plaques. Modalities with clinical applications are given in bold.
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critical lesions are identified, tailored interventions may reduce the
risk of complications caused by the prospective culprit lesion.
However, optimal management of unstable plaques remains to
be defined and tested prospectively. Preventive or therapeutic
options may include minimizing risk factors using life style
changes, systemic drug therapy such as statins that reduce inflam-
mation, and mechanical ‘plaque sealing’ using PCI. Currently, it is
unclear if invasive ‘cool down’ of inflamed atherosclerotic lesions
has a favourable risk–benefit ratio. Thus, the appropriate use of
any plaque imaging modality and consecutive interventions need
to be investigated in prospective clinical trials, ultimately leading
to guidelines for identification, risk stratification, and therapy of
patients with unstable plaques.
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Tuberculous pericarditis with constrictive physiology
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A previously healthy 28-year-old man presented
with 1 week’s history of chest pain, low-grade
fever, and progressive dyspnoea. Minimal electro-
cardiographic changes were found; however,
cardiac ultrasound revealed moderate amounts of
pericardial fluid, inferolateral hypokinesia, and a
left ventricular ejection fraction of 40% (Panel 1,
arrow points to pericardial effusion). Computed
tomographic thorax showed mediastinal lymphade-
nopathy and discrete left upper lobe infiltrates
(Panel 2, arrow points to left upper lobe infiltrates).
Pericardial drainage was performed, with initial
negative diagnostic results.
Tuberculin skin test and an interferon-g release
assay for tuberculosis were both positive, and
therapy for presumptive tuberculous pericarditis
was initiated, including prednisolone. The diagnosis
was later confirmed by positive cultures for
Mycobacterium tuberculosis from sputum and peri-
cardial fluid. Further testing showed resistance to
several first-line tuberculosis drugs.
At this time, the patient had developed signs of
increased central venous pressure and tachycardia without recurrent pericardial effusion. Cardiac magnetic resonance imaging
showed signs of constriction with a diastolic septal shift (Panel 3, arrow points to diastolic shift of the septem). The visceral and parietal
layers of the pericardium were markedly thickened (measuring 5–10 mm) and showed late gadolinium enhancement (Panels 4 and 5,
arrow points to the visceral and parietal layers of the pericardium).
Antituberculous therapy was modified, and the dose of steroids has been gradually tapered. Hitherto, the patient’s cardiac condition
has been stabile without overt signs of heart failure and with increased exercise capacity, so pericardial surgery has been postponed.
Multidrug-resistant tuberculosis with constrictive pericarditis is exceedingly rare. A multidisciplinary imaging approach was helpful in
determining the extent of cardiac involvement and will be used to assess the therapeutic outcome of this potentially reversible
condition.
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